Project Confirm: Accelerated Drug Approvals for CML-Response
Clin Cancer Res
.
2024 Jan 5;30(1):237-238.
doi: 10.1158/1078-0432.CCR-23-3234.
Authors
Kendra L Sweet
1
,
Jorge E Cortes
2
,
Jane F Apperley
3
,
Mel Mann
4
,
Michael J Mauro
5
,
Vivian G Oehler
6
,
Cristina Ruiz
4
,
Charles A Schiffer
7
,
Lori A Ehrlich
8
,
Gulsum E Pamuk
8
,
Joseph Wynne
8
,
Gautam U Mehta
8
,
Olanrewaju O Okusanya
8
,
R Angelo de Claro
8
,
Marc R Theoret
9
,
B Douglas Smith
10
,
Kelly J Norsworthy
8
Affiliations
1
Moffitt Cancer Center, Tampa, Florida.
2
Georgia Cancer Center, Augusta University, Augusta, Georgia.
3
Centre for Haematology, Imperial College, London, United Kingdom.
4
Patient Advocate, Jonesboro, Georgia.
5
Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York City, New York.
6
Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington.
7
Department of Hematology-Oncology, Karmanos Cancer Center at Wayne State University, Detroit, Michigan.
8
Center for Drug Evaluation and Research, FDA, Washington, District of Columbia.
9
Oncology Center of Excellence, FDA, Washington, District of Columbia.
10
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
PMID:
38178776
PMCID:
PMC10783534
DOI:
10.1158/1078-0432.CCR-23-3234
No abstract available
Publication types
Letter
Kommentar
MeSH terms
Antineoplastic Agents* / therapeutic use
Drug Approval*
Humans
Imatinib Mesylate
Substances
Antineoplastic Agents
Imatinib Mesylate
Grants and funding
FD999999/ImFDA/Intramural FDA HHS/United States